Arbutus Biopharma Corp (ABUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.11 Million) by net assets ($260.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Arbutus Biopharma Corp to measure how many days the company can operate on defensive assets alone.
Arbutus Biopharma Corp - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Arbutus Biopharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arbutus Biopharma Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arbutus Biopharma Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pearl Global Industries Limited
NSE:PGIL
|
0.190x |
|
Ultra Jaya Milk Industry Tbk
JK:ULTJ
|
0.069x |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
0.059x |
|
Delta Israel Brands Ltd
TA:DLTI
|
0.164x |
|
Apacer Technology Inc
TW:8271
|
0.014x |
|
Shenzhen Sea Star Technology
SHE:002137
|
0.031x |
|
STEVANATO GROUP SPA O.N.
F:87N
|
0.049x |
|
Apotea
ST:APOTEA
|
0.120x |
Annual Cash Flow Conversion Efficiency for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual cash flow conversion efficiency of Arbutus Biopharma Corp from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see ABUS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $76.58 Million | $-39.64 Million | -0.518x | +22.28% |
| 2024-12-31 | $97.37 Million | $-64.85 Million | -0.666x | +17.83% |
| 2023-12-31 | $106.02 Million | $-85.94 Million | -0.811x | -213.75% |
| 2022-12-31 | $136.85 Million | $-35.36 Million | -0.258x | +35.18% |
| 2021-12-31 | $169.44 Million | $-67.53 Million | -0.399x | +21.00% |
| 2020-12-31 | $101.97 Million | $-51.44 Million | -0.504x | +48.32% |
| 2019-12-31 | $72.74 Million | $-71.01 Million | -0.976x | -187.85% |
| 2018-12-31 | $200.23 Million | $-67.90 Million | -0.339x | -27.34% |
| 2017-12-31 | $182.50 Million | $-48.60 Million | -0.266x | +6.61% |
| 2016-12-31 | $203.00 Million | $-57.88 Million | -0.285x | -185.06% |
| 2015-12-31 | $547.68 Million | $-54.78 Million | -0.100x | +29.13% |
| 2014-12-31 | $88.00 Million | $-12.42 Million | -0.141x | -23.99% |
| 2013-12-31 | $59.19 Million | $-6.74 Million | -0.114x | -114.00% |
| 2012-12-31 | $40.92 Million | $33.27 Million | 0.813x | +156.28% |
| 2011-12-31 | $5.21 Million | $-7.52 Million | -1.445x | -37.84% |
| 2010-12-31 | $10.73 Million | $-11.25 Million | -1.048x | -608.93% |
| 2009-12-31 | $35.44 Million | $-5.24 Million | -0.148x | +33.28% |
| 2008-12-31 | $38.29 Million | $-8.48 Million | -0.222x | -49.67% |
| 2007-12-31 | $18.37 Million | $-2.72 Million | -0.148x | +99.12% |
| 2006-12-31 | $155.53K | $-2.62 Million | -16.866x | -2240.30% |
| 2005-12-31 | $-18.49 Million | $-14.57 Million | 0.788x | -17.14% |
| 2004-12-31 | $-10.50 Million | $-9.98 Million | 0.951x | +253.00% |
| 2003-12-31 | $43.38 Million | $-26.96 Million | -0.622x | -55.24% |
| 2002-12-31 | $45.35 Million | $-18.16 Million | -0.400x | -146.08% |
| 2001-12-31 | $61.49 Million | $-10.00 Million | -0.163x | +41.51% |
| 2000-12-31 | $30.03 Million | $-8.35 Million | -0.278x | -9.37% |
| 1999-12-31 | $26.88 Million | $-6.84 Million | -0.254x | +52.39% |
| 1998-12-31 | $14.43 Million | $-7.71 Million | -0.534x | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more